Olema Pharmaceuticals, Inc. announced results from a Phase 2 clinical study of palazestrant (OP-1250), the Company's complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD), for the treatment of metastatic ER+/HER2- breast cancer. Such forward-looking statements include, without limitation, statements regarding research and clinical development plans, the scope, progress, results and costs of developing product candidate or any other future product candidates, expected manufacturing capabilities, strategy, regulatory matters, including the timing and likelihood of success of obtaining drug approvals, the timelines for potential clinical study results and initiation of clinical trials of palazestrant (op-1250) as a monotherapy and in combination trials, including OPERA-01, the Company's pivotal Phase 3 monotherapy clinical trial, the potential beneficial characteristics, safety, tolerability, efficacy and therapeutic effects of palazestrant, the development of palazestrant, The potential of palazestrant to become a best-in-class treatment option for ER+/HER2- metastatic breast cancer, improve the standard-of-care treatment, or become a transformative therapy for women living with breast cancer, the combinability of palazestrant with other drugs, market size and opportunity, ability to penetrate the market, the ability to complete certain milestones, and financial condition, cash position, cash runway, and sufficiency of financial resources.